Cannabis with high cannabidiol content is associated with fewer psychotic experiences

Schizophrenia Research

Volumn 130, Issue 1-3, 2011, Pages 216-221

  Schubart, Christian D ^a   Sommer, Iris E C ^a   van Gastel, Willemijn A ^a   Goetgebuer, Rogier L ^a   Kahn, René S ^a   Boks, Marco P M ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cannabidiol; Cannabis; Delta 9 tetrahydrocannabinol; Psychosis; Psychotic symptoms; Schizophrenia

Indexed keywords

CANNABIDIOL; CANNABIS; DRONABINOL;

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DRUG USE; EXPERIENCE; FEMALE; HUMAN; INTERNET; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSIS; QUESTIONNAIRE; SCORING SYSTEM; SELF REPORT;

ADOLESCENT; AGE OF ONSET; ANALYSIS OF VARIANCE; CANNABINOIDS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INTERNET; MALE; MARIJUANA ABUSE; NETHERLANDS; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; SELF REPORT; TETRAHYDROCANNABINOL; TIME FACTORS; YOUNG ADULT;

EID: 79960323467     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.04.017     Document Type: Article

References (36)

1. Arseneault L., Cannon M., Witton J., Murray R.M. Causal association between cannabis and psychosis: examination of the evidence. Br. J. Psychiatry 2004, 184:110-117.
2. Balter K.A., Balter O., Fondell E., Lagerros Y.T. Web-based and mailed questionnaires: a comparison of response rates and compliance. Epidemiology 2005, 16:577-579.
3. Bhattacharyya S., Morrison P.D., Fusar-Poli P., Martin-Santos R., Borgwardt S., Winton-Brown T., Nosarti C., O' Carroll C.M., Seal M., Allen P., Mehta M.A., Stone J.M., Tunstall N., Giampietro V., Kapur S., Murray R.M., Zuardi A.W., Crippa J.A., Atakan Z., McGuire P.K. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010, 35:764-774.
4. Bieleman, B., Beelen, A., Nijkamp, R. and de Bie, E. Coffeeshops in Nederland 2007. 2008. Groningen, WODC/St.Intraval. Ref Type: Report.
5. DeLisi L.E. The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia?. Curr. Opin. Psychiatry 2008, 21:140-150.
6. Di Forti F.M., Morgan C., Dazzan P., Pariante C., Mondelli V., Marques T.R., Handley R., Luzi S., Russo M., Paparelli A., Butt A., Stilo S.A., Wiffen B., Powell J., Murray R.M. High-potency cannabis and the risk of psychosis. Br. J. Psychiatry 2009, 195:488-491.
7. Ekman A., Dickman P.W., Klint A., Weiderpass E., Litton J.E. Feasibility of using web-based questionnaires in large population-based epidemiological studies. Eur. J. Epidemiol. 2006, 21:103-111.
8. Elsohly M.A., Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005, 78:539-548.
9. Fusar-Poli P., Allen P., Bhattacharyya S., Crippa J.A., Mechelli A., Borgwardt S., Martin-Santos R., Seal M.L., O'Carrol C., Atakan Z., Zuardi A.W., McGuire P. Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int. J. Neuropsychopharmacol. 2010, 13:421-432.
10. Gosling S.D., Vazire S., Srivastava S., John O.P. Should we trust web-based studies? A comparative analysis of six preconceptions about internet questionnaires. Am. Psychol. 2004, 59:93-104.
11. King L. Understanding cannabis potency and monitoring cannabis products in Europe. Monograph 2008, vol. 1:242-259. European Monitoring Centre for Drugs and Drug Addiction, Lisbon. S.R. Sznitman, B. Olsson, R. Room (Eds.).
12. Konings M., Bak M., Hanssen M., van O.J., Krabbendam L. Validity and reliability of the CAPE: a self-report instrument for the measurement of psychotic experiences in the general population. Acta Psychiatr. Scand. 2006, 114:55-61.
13. Konings M., Henquet C., Maharajh H.D., Hutchinson G., van O.J. Early exposure to cannabis and risk for psychosis in young adolescents in Trinidad. Acta Psychiatr. Scand. 2008.
14. Kuepper R., van O.J., Lieb R., Wittchen H.U., Hofler M., Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ 2011, 342:d738.
15. Leweke F.M., Schneider U., Radwan M., Schmidt E., Emrich H.M. Different effects of nabilone and cannabidiol on binocular depth inversion in Man. Pharmacol. Biochem. Behav. 2000, 66:175-181.
16. Macleod J., Oakes R., Copello A., Crome I., Egger M., Hickman M., Oppenkowski T., Stokes-Lampard H., Davey S.G. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet 2004, 363:1579-1588.
17. McGrath J., Welham J., Scott J., Varghese D., Degenhardt L., Hayatbakhsh M.R., Alati R., Williams G.M., Bor W., Najman J.M. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch. Gen. Psychiatry 2010.
18. McLaren J., Swift W., Dillon P., Allsop S. Cannabis potency and contamination: a review of the literature. Addiction 2008, 103:1100-1109.
19. Mechoulam R., Gaoni Y. A total synthesis of dl-delta-1-tetrahydrocannabinol. The active constituent of hashish. J. Am. Chem. Soc. 1965, 87:3273-3275.
20. Mehmedic Z., Chandra S., Slade D., Denham H., Foster S., Patel A.S., Ross S.A., Khan I.A., Elsohly M.A. Potency trends of Delta(9)-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J. Forensic Sci. 2010.
21. Meyerson P., Tryon W.W. Validating internet research: a test of the psychometric equivalence of internet and in-person samples. Behav. Res. Methods Instrum. Comput. 2003, 35:614-620.
22. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
23. Morgan C.J., Curran H.V. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br. J. Psychiatry 2008, 192:306-307.
24. Potter D.J., Clark P., Brown M.B. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J. Forensic Sci. 2008, 53:90-94.
25. Rottanburg D., Robins A.H., Ben-Arie O., Teggin A., Elk R. Cannabis-associated psychosis with hypomanic features. Lancet 1982, 2:1364-1366.
26. Schubart, C.D., van Gastel, W.A., Breetvelt, E.J., Beetz, S.L., Ophoff, R.A., Sommer, I.E., Kahn, R.S. and Boks, M.P. Cannabis use at young age is associated with psychotic experiences. Psychological Medicine. 2010.Ref Type: In Press.
27. Skinner R., Conlon L., Gibbons D., McDonald C. Cannabis use and non-clinical dimensions of psychosis in university students presenting to primary care. Acta Psychiatr. Scand. 2010.
28. Smith N. High potency cannabis: the forgotten variable. Addiction 2005, 100:1558-1560.
29. Stefanis N.C., Hanssen M., Smirnis N.K., Avramopoulos D.A., Evdokimidis I.K., Stefanis C.N., Verdoux H., Van O.J. Evidence that three dimensions of psychosis have a distribution in the general population. Psychol. Med. 2002, 32:347-358.
30. Trimbos, T.N.I.o.M.H.a.A. THC-concentraties in wiet, nederwiet en hasj in Nederlands coffeeshops (2007-2008). 1-1-2008. Ref Type: Generic.
31. Trimbos, T.N.I.o.M.H.a.A. THC-concentraties in wiet, nederwiet en hasj in Nederlands coffeeshops (2008-2009). 1-1-2009. Ref Type: Generic.
32. United Nations Office on Drugs and Crime. World Drug Report 2009. 1-1-2009. Ref Type: Report.
33. Zuardi A.W., Shirakawa I., Finkelfarb E., Karniol I.G. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl.) 1982, 76:245-250.
34. Zuardi A.W., Morais S.L., Guimaraes F.S., Mechoulam R. Antipsychotic effect of cannabidiol. J. Clin. Psychiatry 1995, 56:485-486.
35. Zuardi A.W., Crippa J.A., Hallak J.E., Moreira F.A., Guimaraes F.S. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz. J. Med. Biol. Res. 2006, 39:421-429.
36. Zuardi A.W., Hallak J.E., Dursun S.M., Morais S.L., Sanches R.F., Musty R.E., Crippa J.A. Cannabidiol monotherapy for treatment-resistant schizophrenia. J. Psychopharmacol. 2006, 20:683-686.